Barcelona, Spain – Different types of cancer have unique molecular ‘fingerprints’ which are detectable in early stages of the disease and can be picked up with near-perfect accuracy by small, portable scanners in just a few hours, according to a study published today in the journal Molecular Cell. The discovery...
research News
NEW YORK, NY – Using artificial intelligence, Ludwig Cancer Research scientists have developed a powerful predictive model for identifying the most potent cancer killing immune cells for use in cancer immunotherapies. Combined with additional algorithms, the predictive model, described in the current issue of the journal Nature Biotechnology, can be...
Edmonton, Alberta – A new case report published in the peer-reviewed OMICS: A Journal of Integrative Biology describes how longitudinal multi-omics monitoring (LMOM) helped to detect a precancerous pancreatic tumor and led to a successful surgical intervention. Click here to read the article. The patient had undergone annual blood-based LMOM, in which 143 endogenous...
Houston, Texas – A researcher at the University of Houston College of Pharmacy Drug Discovery Institute is working to revolutionize treatment regimens for triple-negative breast cancer (TNBC) by proving that nebivolol, an FDA-approved drug for high blood pressure, is effective in treating it. Meghana Trivedi, professor of Pharmacy and Pharmacology,...
REDWOOD CITY, Calif. — Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the completion of enrollment in its RZ402 Phase 2 study in diabetic macular edema (“DME”). RZ402 is a selective and potent plasma kallikrein inhibitor (“PKI”) being developed...
HOUSTON, Texas – Rice University bioengineers have developed a new construction kit for building custom sense-and-respond circuits in human cells. The research, published in the journal Science, represents a major breakthrough in the field of synthetic biology that could revolutionize therapies for complex conditions like autoimmune disease and cancer. “Imagine...
Houston, TX – Cancers begin with abnormal changes in individual cells, and the ability to track the accumulation of mutations at the single-cell level can shed new light on the early stages of the disease. Such knowledge could enable more effective early detection and treatment options for patients as well...
SOUTH SAN FRANCISCO, Calif. — Rigel Pharmaceuticals, Inc. today announced a collaboration with CONNECT, an international collaborative network of pediatric cancer centers, to conduct a Phase 2 clinical trial to evaluate REZLIDHIA® (olutasidenib) in combination with temozolomide as maintenance therapy in newly diagnosed pediatric and young adult patients with high-grade glioma...
Colorectal cancer rates are rising in adults younger than 50 with the biggest jump, more than 5 percent, recorded in those ages 20 to 29, a study found. People older than age 50 began getting tested routinely for the disease in the mid-1980s, leading to a 2.8 percent yearly decline...
Kuopio, Finland – A risk model developed by researchers can help to identify cancer patients who could benefit from immune checkpoint inhibitors, ICIs. Published in BMC Cancer, the study was conducted at the University of Eastern Finland and Kuopio University Hospital. Immune checkpoint inhibitors are used to treat a variety...